Related Experiment Video
Updated: Jul 9, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.0K
Risankizumab in Adults with Psoriatic Arthritis
Karla Machlab1, Jensen Yeung2,3, Melinda Gooderham4,5,6
1Department of Medicine, University of Toronto, ON, Canada.
Skin Therapy Letter
|November 28, 2023
Summary
Risankizumab effectively treats psoriatic arthritis (PsA) by targeting interleukin-23. Clinical trials confirm its safety and efficacy in reducing joint swelling and skin lesions, improving patient quality of life.
Area of Science:
- Immunology
- Rheumatology
- Dermatology
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition affecting joints and skin in psoriasis patients.
- Interleukin-23 (IL-23) plays a key role in PsA pathophysiology, driving inflammation and bone remodeling.
- Current treatments aim to manage PsA symptoms and underlying immune dysregulation.
Purpose of the Study:
- To review the efficacy and safety of risankizumab for psoriatic arthritis treatment.
- To present week 24 and 52 clinical trial results for risankizumab in PsA.
- To evaluate risankizumab's impact on joint, skin, and quality of life outcomes.
Main Methods:
- Phase 2 and 3 clinical trials were conducted to assess risankizumab in PsA patients.
- Risankizumab, a monoclonal antibody targeting IL-23, was administered to participants.
- Efficacy endpoints included joint counts, skin clearance, and quality of life measures.
Main Results:
- Risankizumab demonstrated significant efficacy in reducing swollen and tender joint counts.
- Psoriatic plaque clearance and improvements in patient-reported quality of life were observed.
- The treatment was well-tolerated, with upper respiratory tract infections as the most common adverse event.
Conclusions:
- Risankizumab is a safe and effective therapeutic option for moderate-to-severe psoriatic arthritis.
- Targeting IL-23 with risankizumab offers a valuable treatment strategy for PsA.
- Long-term data support the sustained benefit and tolerability of risankizumab in PsA management.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188
01:29Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
01:22iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K